Roger S. McIntyre, MD, FRCPC
a:3:{i:0;s:73:"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada";i:1;s:90:"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada";i:2;s:254:"
Original Research
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
July 7, 2025
The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
Academic Highlights
Dysregulation of Noradrenergic Activity
November 8, 2024
Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
Original Research
Risk-Sensitive Decision-Making and Self-Harm
September 6, 2023
Greater risk-taking has been associated with suicide attempts in youth with major depression. This study examined whether the association between self-harm and risk-sensitive decision-making is true for bipolar disorder...
Original Research
Vortioxetine vs Desvenlafaxine in Patients With MDD
May 22, 2023
Compared with desvenlafaxine, vortioxetine was associated with higher rates of symptomatic and functional remission, better daily and social functioning, and greater treatment satisfaction in patients with major depression and...
Academic Highlights
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
September 7, 2022
Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...
